Johnson & Johnson (JNJ)

172.20
NYSE
Prev Close 172.18
Day Low/High 171.84 / 172.98
52 Wk Low/High 133.65 / 173.65
Exchange NYSE
Shares Outstanding 2633.40B
Market Cap 453.42B
P/E Ratio 28.74
Div & Yield N.A. (N.A)

Johnson & Johnson Cut to Neutral at UBS

Jim Cramer: CEOs Better Come Out Jacked on Their Conference Calls

Jim Cramer: CEOs Better Come Out Jacked on Their Conference Calls

Stop apologizing, don't surrender to the gloom and tell your story with sympathy but with glory, and don't make us feel like it's a mistake to own shares in your company.

Mid-Caps Outperform, Funding 'Paycheck Protection', U.K. Vaccine Trials

Mid-Caps Outperform, Funding 'Paycheck Protection', U.K. Vaccine Trials

Trading volumes dropping on major indexes, U.K. teams begin human trials on a Covid-19 vaccine, and the U.S. Senate wants another stimulus package addition.

Jim Cramer: How to Stay Safe, Until Quick Testing for Covid-19 Is Available

Jim Cramer: How to Stay Safe, Until Quick Testing for Covid-19 Is Available

Welcome to the new era. Social distancing is not without risks, but it is as good as it gets.

Futures Pop, Gilead's Covid-19 Treatment, Trading My 'Virus Group'

Futures Pop, Gilead's Covid-19 Treatment, Trading My 'Virus Group'

The rise in equity futures pricing was born of optimism from the president's task force draft guideline on reopening parts of the U.S. economy and Gilead Sciences' somewhat positive results on its remdisivir anti-viral treatment.

My New Multi-Group Portfolio Strategy for Trading the Pandemic

My New Multi-Group Portfolio Strategy for Trading the Pandemic

How has my book evolved since the Fed and Treasury rode into town? Here's how.

5 Ways to Invest in Testing, Vaccines and Clinical Trials

5 Ways to Invest in Testing, Vaccines and Clinical Trials

These companies have the potential to help in battling the Covid-19 pandemic.

Jim Cramer: I Don't Think Covid-19 Is Invincible

Jim Cramer: I Don't Think Covid-19 Is Invincible

When it's beaten you will wish you own stocks, especially the stocks that are right now lethal to your portfolio.

Jim Cramer: Don't Mistake the Rally for Cheering

Jim Cramer: Don't Mistake the Rally for Cheering

There is no joy in stockville -- instead we have big companies with stocks rising. Here's why that is and what you need to understand about the rally amid the crisis.

These 3 Earnings Reports Illustrate What We Are Likely to See This Season

These 3 Earnings Reports Illustrate What We Are Likely to See This Season

Earnings season started with a mixed bag of reports.

Johnson & Johnson's Price Strength Is Ripping the Band-Aid Off This Rally

Johnson & Johnson's Price Strength Is Ripping the Band-Aid Off This Rally

Long-time investors in JNJ are probably not surprised how well the stock has responded in the past few weeks.

Johnson & Johnson Turns in Decent Results -- But That's Not Why I'm in the Stock

Johnson & Johnson Turns in Decent Results -- But That's Not Why I'm in the Stock

There are plenty of good reasons to invest in JNJ, but one resonates with me more than any other.

Inflationary Concerns, Banks Report Earnings, Netflix Soars: Market Recon

Inflationary Concerns, Banks Report Earnings, Netflix Soars: Market Recon

I did warn publicly back in another epoch that quantitative easing would lead toward increased consumer level inflation.

Will the Market Say, 'No Guidance, No Problem' This Earnings Season?

Will the Market Say, 'No Guidance, No Problem' This Earnings Season?

In view of the obvious economic issues that the market faces, it is interesting that sentiment is not more negative.

The Virus Remains in Control, Unrealistic V-Shaped Recovery, Trading 2 Stocks

The Virus Remains in Control, Unrealistic V-Shaped Recovery, Trading 2 Stocks

I do think the key to reopening this economy is one of greatly expanded testing for Covid-19, once a reliable treatment has made it past clinical testing, and into mass production.

Jim Cramer: Finding Any Stocks With No Hair?

Jim Cramer: Finding Any Stocks With No Hair?

After a company reports we all know what's wrong, it's immunized. And that's when you can buy.

Jim Cramer: Goodbye to a Horrid Quarter

Jim Cramer: Goodbye to a Horrid Quarter

Now that the service economy is pretty much stopped in its tracks, here are promising areas, including technology as manufacturing, to consider.

Good-Bye to March 2020, Retailmageddon, 32% Unemployment? Trading DocuSign

Good-Bye to March 2020, Retailmageddon, 32% Unemployment? Trading DocuSign

I don't think it would be too much of a stretch to imagine that too many investors, or citizens for that matter, will mind seeing March 2020 head on out of here.

Jim Cramer: Here's the Science Behind Our Rally

Jim Cramer: Here's the Science Behind Our Rally

While Johnson & Johnson and other pharma cos. give us hope, here's my wish list to keep the nation safe and the economy ready to go again.

Johnson & Johnson Is Ready to Rally After Reaching a Downside Price Target

Johnson & Johnson Is Ready to Rally After Reaching a Downside Price Target

While the short-term picture of JNJ suggests more risk is possible, the longer-term patterns are constructive.

3 Japanese Stocks Getting a Boost on Potential Coronavirus Treatments

3 Japanese Stocks Getting a Boost on Potential Coronavirus Treatments

Japan is a leader in pharmaceuticals and has three companies working overtime to develop treatments for Covid-19.

3 Strong Long-Term Buys for Uncertain Times

3 Strong Long-Term Buys for Uncertain Times

These pharmaceutical names have what it takes amid the current crisis and for the long run.

Good Medicine for a Retest? Johnson & Johnson

Good Medicine for a Retest? Johnson & Johnson

A strong S&P for three days makes me leery of what's ahead, but here's an option in JNJ.

Jim Cramer: Here's What Can Be Bought, Sold Right Now

Jim Cramer: Here's What Can Be Bought, Sold Right Now

The Holy Grail right now are the few companies thriving and that will keep going after this is over, but there are others who will rebound and some who will not.

Johnson & Johnson Weathers Storm but Needs to Build a New Base

Johnson & Johnson Weathers Storm but Needs to Build a New Base

The healthcare giant's charts still show some signs of weakness but also indicate it could rally and make a base from a higher level.

This Health Care Dividend King Offers a Remedy for Hopeless Investors

This Health Care Dividend King Offers a Remedy for Hopeless Investors

JNJ should survive a recession and prove in demand in a health crisis.

Jim Cramer: What to Buy and What to Sell Now, Part 2

Jim Cramer: What to Buy and What to Sell Now, Part 2

In the 2nd of a 3-part series, Jim Cramer goes through all 30 Dow stocks to evaluate what is safe to buy and what you should sell or avoid (like the plague).

The Charts of Johnson & Johnson Show What It's Made Of

The Charts of Johnson & Johnson Show What It's Made Of

The company has grown organically and by acquisitions. It has dealt with adversity and bad news.

Jim Cramer: Do You Really Want to Sell Now?

Jim Cramer: Do You Really Want to Sell Now?

The answer to that question depends on several factors, so let's break them down.

Three Strategies for Income Investors

Three Strategies for Income Investors

For reliable income, a portfolio strategy generating monthly payouts, an opportunity in dividend kings, and favorites among taxable bond funds.